IDSA
@idsainfo.bsky.social
A global community of 13,000 clinicians, scientists and public health experts working together to solve humanity’s smallest and greatest challenges, from tiny microbes to global outbreaks.
ID Fellows: Join us for a virtual Fellows Case Conference next Tues. Feb. 17 at 3pm ET for a fellow-led case presentation. Faculty will include Kartikey Acharya, MD, MPH, FACP, of froedtert.bsky.social and Joslyn Strebe, MD, of UT Southwestern Medical Center.
Register: https://bit.ly/4rMhYqe
Register: https://bit.ly/4rMhYqe
February 11, 2026 at 6:06 PM
ID Fellows: Join us for a virtual Fellows Case Conference next Tues. Feb. 17 at 3pm ET for a fellow-led case presentation. Faculty will include Kartikey Acharya, MD, MPH, FACP, of froedtert.bsky.social and Joslyn Strebe, MD, of UT Southwestern Medical Center.
Register: https://bit.ly/4rMhYqe
Register: https://bit.ly/4rMhYqe
In OFID, authors compare clinical outcomes of patients treated with liposomal amphotericin B (L-AmB) versus mold-active triazoles as primary treatment for invasive aspergillosis (IA).
🔗 Article: https://bit.ly/4rsCAn0
📝 Press release: https://bit.ly/46B1rNo
🔗 Article: https://bit.ly/4rsCAn0
📝 Press release: https://bit.ly/46B1rNo
Primary Therapy for Invasive Aspergillosis With Triazoles or L-AmB: A Multicenter Retrospective Study
L-AmB was preferentially used in higher risk patients, including those with hematological malignancies (58.1% vs 30.4% for triazoles) and breakthrough infe
academic.oup.com
February 10, 2026 at 7:48 PM
In OFID, authors compare clinical outcomes of patients treated with liposomal amphotericin B (L-AmB) versus mold-active triazoles as primary treatment for invasive aspergillosis (IA).
🔗 Article: https://bit.ly/4rsCAn0
📝 Press release: https://bit.ly/46B1rNo
🔗 Article: https://bit.ly/4rsCAn0
📝 Press release: https://bit.ly/46B1rNo
Tomorrow! Join us for for a webinar on practical, evidence-based approaches to fungal diagnostic testing.
Presented by Julie M. Steinbrink, MD, MHS, of Duke University and Martin Hönigl, MD, of Medical University of Graz, Austria.
Register: https://bit.ly/3OiX1Ez
Presented by Julie M. Steinbrink, MD, MHS, of Duke University and Martin Hönigl, MD, of Medical University of Graz, Austria.
Register: https://bit.ly/3OiX1Ez
February 9, 2026 at 10:43 PM
Tomorrow! Join us for for a webinar on practical, evidence-based approaches to fungal diagnostic testing.
Presented by Julie M. Steinbrink, MD, MHS, of Duke University and Martin Hönigl, MD, of Medical University of Graz, Austria.
Register: https://bit.ly/3OiX1Ez
Presented by Julie M. Steinbrink, MD, MHS, of Duke University and Martin Hönigl, MD, of Medical University of Graz, Austria.
Register: https://bit.ly/3OiX1Ez
Explore the science shaping the fight against antimicrobial resistance.
jidjournal.bsky.social's new AMR collection, led by Neil Clancy, MD, FIDSA, highlights cutting-edge research on resistance, genomics, new drug development and more: https://bit.ly/4qfYDfN
jidjournal.bsky.social's new AMR collection, led by Neil Clancy, MD, FIDSA, highlights cutting-edge research on resistance, genomics, new drug development and more: https://bit.ly/4qfYDfN
February 8, 2026 at 6:25 PM
Explore the science shaping the fight against antimicrobial resistance.
jidjournal.bsky.social's new AMR collection, led by Neil Clancy, MD, FIDSA, highlights cutting-edge research on resistance, genomics, new drug development and more: https://bit.ly/4qfYDfN
jidjournal.bsky.social's new AMR collection, led by Neil Clancy, MD, FIDSA, highlights cutting-edge research on resistance, genomics, new drug development and more: https://bit.ly/4qfYDfN
IDSA members: Looking to build confidence in compensation negotiation? IDSA offers free, 60-90 min physician-led online informational sessions designed to help increase knowledge about physician compensation negotiation.
Schedule a virtual session: https://bit.ly/3Zdhhdg
Schedule a virtual session: https://bit.ly/3Zdhhdg
February 7, 2026 at 10:22 PM
IDSA members: Looking to build confidence in compensation negotiation? IDSA offers free, 60-90 min physician-led online informational sessions designed to help increase knowledge about physician compensation negotiation.
Schedule a virtual session: https://bit.ly/3Zdhhdg
Schedule a virtual session: https://bit.ly/3Zdhhdg
Among those who are aware of the recent changes to the federal childhood vaccine schedule, more expect the changes to hurt children than help them (54% vs. 26%), a new kff.org poll finds: https://bit.ly/46noew6
KFF Tracking Poll on Health Information and Trust: Trust in the CDC and Views of Federal Childhood Vaccine Schedule Changes | KFF
Weeks after the Trump administration reduced the number of childhood vaccine recommended for routine use, public trust in the CDC is at its lowest since the COVID-19 pandemic, and less than half are confident in federal agencies' ability to make such re...
bit.ly
February 7, 2026 at 3:11 AM
Among those who are aware of the recent changes to the federal childhood vaccine schedule, more expect the changes to hurt children than help them (54% vs. 26%), a new kff.org poll finds: https://bit.ly/46noew6
Join IDSA members Aneesh K. Mehta, MD, FIDSA, FAST, and James Lawler, MD, MPH, FIDSA, next Tues. Feb. 10 at 12pm ET as they present "Infectious Disease: Present and Future Threats," a session hosted by HHS/ASPR Project ECHO Clinical Readiness Rounds.
Learn more and register: https://bit.ly/46nzad6
Learn more and register: https://bit.ly/46nzad6
HHS/ASPR Project ECHO Clinical Readiness Rounds | iECHO
Program Overview
The U.S. Department of Health and Human Services Office of the Administration for Strategic Preparedness and Response (ASPR) and Project ECHO have launched this program designed.....
bit.ly
February 7, 2026 at 12:05 AM
Join IDSA members Aneesh K. Mehta, MD, FIDSA, FAST, and James Lawler, MD, MPH, FIDSA, next Tues. Feb. 10 at 12pm ET as they present "Infectious Disease: Present and Future Threats," a session hosted by HHS/ASPR Project ECHO Clinical Readiness Rounds.
Learn more and register: https://bit.ly/46nzad6
Learn more and register: https://bit.ly/46nzad6
From outbreak response to prevention and policy, infectious disease physicians are shaping public health every day. ID physician Seema Jain, MD, of sfpublichealth.bsky.social shares why a career in public health is never boring.
Explore job paths in ID: https://bit.ly/49MHGmX
Explore job paths in ID: https://bit.ly/49MHGmX
February 6, 2026 at 9:49 PM
From outbreak response to prevention and policy, infectious disease physicians are shaping public health every day. ID physician Seema Jain, MD, of sfpublichealth.bsky.social shares why a career in public health is never boring.
Explore job paths in ID: https://bit.ly/49MHGmX
Explore job paths in ID: https://bit.ly/49MHGmX
Thank you Sen. @bluntrochester.senate.gov for raising concerns about changes to the childhood vaccine schedule and the lack of a transparent, public process during the Feb. 3 NIH hearing.
February 6, 2026 at 7:14 PM
Thank you Sen. @bluntrochester.senate.gov for raising concerns about changes to the childhood vaccine schedule and the lack of a transparent, public process during the Feb. 3 NIH hearing.
Join us next Tues. Feb. 10 at 11am ET for a webinar on practical, evidence-based approaches to fungal diagnostic testing.
Presented by Julie M. Steinbrink, MD, MHS, of Duke University and Martin Hönigl, MD, of Medical University of Graz, Austria.
Register: https://bit.ly/3OiX1Ez
Presented by Julie M. Steinbrink, MD, MHS, of Duke University and Martin Hönigl, MD, of Medical University of Graz, Austria.
Register: https://bit.ly/3OiX1Ez
February 6, 2026 at 1:07 AM
Join us next Tues. Feb. 10 at 11am ET for a webinar on practical, evidence-based approaches to fungal diagnostic testing.
Presented by Julie M. Steinbrink, MD, MHS, of Duke University and Martin Hönigl, MD, of Medical University of Graz, Austria.
Register: https://bit.ly/3OiX1Ez
Presented by Julie M. Steinbrink, MD, MHS, of Duke University and Martin Hönigl, MD, of Medical University of Graz, Austria.
Register: https://bit.ly/3OiX1Ez
Thank you @hickenlooper.senate.gov for calling attention to the promise of mRNA technology and the abrupt cancellation of $500 million in BARDA research.
As you noted, this platform has delivered real successes and continues to show potential, including in cancer research.
As you noted, this platform has delivered real successes and continues to show potential, including in cancer research.
February 5, 2026 at 8:34 PM
Thank you @hickenlooper.senate.gov for calling attention to the promise of mRNA technology and the abrupt cancellation of $500 million in BARDA research.
As you noted, this platform has delivered real successes and continues to show potential, including in cancer research.
As you noted, this platform has delivered real successes and continues to show potential, including in cancer research.
Thank you Senator Roger Marshall for raising the issue of antimicrobial resistance during the Feb. 3 NIH hearing, a critical and growing public health threat.
February 5, 2026 at 8:18 PM
Thank you Senator Roger Marshall for raising the issue of antimicrobial resistance during the Feb. 3 NIH hearing, a critical and growing public health threat.
Thank you Senator Bill Cassidy for raising concerns about the cancellation of mRNA research during the Feb. 3 NIH hearing.
Losing this critical tool in our defense against future pandemics puts both personal health and national security at risk.
Losing this critical tool in our defense against future pandemics puts both personal health and national security at risk.
February 5, 2026 at 8:17 PM
Thank you Senator Bill Cassidy for raising concerns about the cancellation of mRNA research during the Feb. 3 NIH hearing.
Losing this critical tool in our defense against future pandemics puts both personal health and national security at risk.
Losing this critical tool in our defense against future pandemics puts both personal health and national security at risk.
On IDSA’s & HIVMA’s Science Speaks blog: A study in JAC-Antimicrobial Resistance examined differences in the in vitro activity of ampicillin-sulbactam and amoxicillin-clavulanate in several Enterobacterales species. Read IDSA’s Journal Club review by Aldon Li, MD, FIDSA. https://bit.ly/4tdRlvP
Can amoxicillin-clavulanate be used when pathogens are resistant to ampicillin-sulbactam?
A study examined differences in the in vitro activity of ampicillin-sulbactam and amoxicillin-clavulanate in several Enterobacterales species. Read IDSA's Journal Club review by Aldon Li, MD, FIDSA.
www.idsociety.org
February 5, 2026 at 3:44 AM
On IDSA’s & HIVMA’s Science Speaks blog: A study in JAC-Antimicrobial Resistance examined differences in the in vitro activity of ampicillin-sulbactam and amoxicillin-clavulanate in several Enterobacterales species. Read IDSA’s Journal Club review by Aldon Li, MD, FIDSA. https://bit.ly/4tdRlvP
The bipartisan PASTEUR Act was reintroduced today to combat antimicrobial resistance and improve access to life-saving antibiotics and antifungals: bit.ly/4kemF9o
Thank you Reps. Buddy Carter, Scott Peters, Nick Langworthy, Mike Levin and Mike Carey for your leadership.
Thank you Reps. Buddy Carter, Scott Peters, Nick Langworthy, Mike Levin and Mike Carey for your leadership.
February 4, 2026 at 8:22 PM
The bipartisan PASTEUR Act was reintroduced today to combat antimicrobial resistance and improve access to life-saving antibiotics and antifungals: bit.ly/4kemF9o
Thank you Reps. Buddy Carter, Scott Peters, Nick Langworthy, Mike Levin and Mike Carey for your leadership.
Thank you Reps. Buddy Carter, Scott Peters, Nick Langworthy, Mike Levin and Mike Carey for your leadership.
Kidney transplantation (KT) from donors with HIV to recipients with HIV is noninferior to KT from donors without HIV in terms of safety. In CID, authors describe the burden and timeline of post-KT infections and assess associations with HIV donor status. https://bit.ly/4jNGe8D
Infections After Kidney Transplantation From Donors With Human Immunodeficiency Virus (HIV) to Recipients With HIV
Among 198 kidney transplant recipients with HIV, the rate and spectrum of posttransplant infections were similar regardless of donor HIV status. HIV donor-
bit.ly
February 3, 2026 at 8:10 PM
Kidney transplantation (KT) from donors with HIV to recipients with HIV is noninferior to KT from donors without HIV in terms of safety. In CID, authors describe the burden and timeline of post-KT infections and assess associations with HIV donor status. https://bit.ly/4jNGe8D
Spotlight the incredible work of your colleagues. 🌟🔦 Nominations for the 2026 IDSA and HIVMA Society Awards are now open! Submit your nomination now through April 7: https://idsociety.org/about-idsa/society-awards/
February 2, 2026 at 9:43 PM
Spotlight the incredible work of your colleagues. 🌟🔦 Nominations for the 2026 IDSA and HIVMA Society Awards are now open! Submit your nomination now through April 7: https://idsociety.org/about-idsa/society-awards/
The second installment of the ID Clinical Bootcamp for APPs, with new content from the #IDWeek2025 premeeting workshop, is available as an accredited course on the IDSA Academy!
Register by Feb. 28 with the code APPBOOTCAMP to claim a 10% discount: https://bit.ly/3Nh09jR
Register by Feb. 28 with the code APPBOOTCAMP to claim a 10% discount: https://bit.ly/3Nh09jR
January 31, 2026 at 8:15 PM
The second installment of the ID Clinical Bootcamp for APPs, with new content from the #IDWeek2025 premeeting workshop, is available as an accredited course on the IDSA Academy!
Register by Feb. 28 with the code APPBOOTCAMP to claim a 10% discount: https://bit.ly/3Nh09jR
Register by Feb. 28 with the code APPBOOTCAMP to claim a 10% discount: https://bit.ly/3Nh09jR
Browse the best of 2025! The Editors-in-Chief of cidjournal.bsky.social, jidjournal.bsky.social & ofidjournal.bsky.social have selected a collection of outstanding articles from 2025. Explore research on long COVID, AMR, HIV, influenza, vaccines & more: https://bit.ly/49Xgge6
paulsaxmd.bsky.social
paulsaxmd.bsky.social
January 30, 2026 at 9:53 PM
Browse the best of 2025! The Editors-in-Chief of cidjournal.bsky.social, jidjournal.bsky.social & ofidjournal.bsky.social have selected a collection of outstanding articles from 2025. Explore research on long COVID, AMR, HIV, influenza, vaccines & more: https://bit.ly/49Xgge6
paulsaxmd.bsky.social
paulsaxmd.bsky.social
Thank you @bluntrochester.senate.gov for standing up for evidence-based vaccine policy and children’s health.
IDSA supports this letter from Members of Congress to RFK Jr. to reinstate the evidence-based childhood immunization schedule: bit.ly/4k52riB
IDSA supports this letter from Members of Congress to RFK Jr. to reinstate the evidence-based childhood immunization schedule: bit.ly/4k52riB
bit.ly
January 29, 2026 at 7:41 PM
Thank you @bluntrochester.senate.gov for standing up for evidence-based vaccine policy and children’s health.
IDSA supports this letter from Members of Congress to RFK Jr. to reinstate the evidence-based childhood immunization schedule: bit.ly/4k52riB
IDSA supports this letter from Members of Congress to RFK Jr. to reinstate the evidence-based childhood immunization schedule: bit.ly/4k52riB
The IDSA Foundation strengthens the infectious diseases workforce, advances research, and promotes equity in the fight against global ID threats.
Learn more: idsafoundation.org
Learn more: idsafoundation.org
January 29, 2026 at 2:06 PM
The IDSA Foundation strengthens the infectious diseases workforce, advances research, and promotes equity in the fight against global ID threats.
Learn more: idsafoundation.org
Learn more: idsafoundation.org
Subcutaneous antibiotic administration is increasingly recognized as a valuable alternative to intravenous therapy in selected clinical contexts. In CID, authors summarize current clinical experience, PK/PD data, and technical aspects of subcutaneous infusion. https://bit.ly/3NB1jH5
When and How to Use Subcutaneous Antibiotics
Subcutaneous administration of selected antibiotics provides a practical, safe alternative to intravenous therapy in patients with poor venous access, in o
academic.oup.com
January 28, 2026 at 6:09 PM
Subcutaneous antibiotic administration is increasingly recognized as a valuable alternative to intravenous therapy in selected clinical contexts. In CID, authors summarize current clinical experience, PK/PD data, and technical aspects of subcutaneous infusion. https://bit.ly/3NB1jH5
IDSA is alarmed by reports of immigration enforcement activity occurring near health care settings. Health care professionals must be able to do their jobs without barriers that undermine patient trust or compromise care.
Our statement: https://bit.ly/3NKXjUA
Our statement: https://bit.ly/3NKXjUA
January 27, 2026 at 10:09 PM
IDSA is alarmed by reports of immigration enforcement activity occurring near health care settings. Health care professionals must be able to do their jobs without barriers that undermine patient trust or compromise care.
Our statement: https://bit.ly/3NKXjUA
Our statement: https://bit.ly/3NKXjUA
The administration’s “anti-vaccine stance has interrupted the reliable flow of the data we need to keep Americans safe from preventable infections,” writes IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, in a new @annalsofim.bsky.social editorial. www.acpjournals.org/doi/10.7326/...
Tampering With Evidence: Selective Silencing of Timely Public Health Data | Annals of Internal Medicine
www.acpjournals.org
January 27, 2026 at 8:20 PM
The administration’s “anti-vaccine stance has interrupted the reliable flow of the data we need to keep Americans safe from preventable infections,” writes IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, in a new @annalsofim.bsky.social editorial. www.acpjournals.org/doi/10.7326/...
ID physicians see the devastating consequences of vaccine-preventable diseases every day, & now more than ever, families & clinicians need accurate information & evidence-based recommendations they can trust.
IDSA endorses AAP's 2026 childhood immunization schedule.
@ameracadpeds.bsky.social
IDSA endorses AAP's 2026 childhood immunization schedule.
@ameracadpeds.bsky.social
January 27, 2026 at 2:54 PM
ID physicians see the devastating consequences of vaccine-preventable diseases every day, & now more than ever, families & clinicians need accurate information & evidence-based recommendations they can trust.
IDSA endorses AAP's 2026 childhood immunization schedule.
@ameracadpeds.bsky.social
IDSA endorses AAP's 2026 childhood immunization schedule.
@ameracadpeds.bsky.social